GS-441524

active metabolite of remdesivir

Also Known As:

(13C3)-GS-441524; (2R,3R,4S,5R)-2-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furancarbonitrile; 13C3 GS-441524; 13C3-GS-441524; 2-C-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2,5-anhydro-D-altrononitrile; GS 441524; GS-441285; GS-828840; GS441524

Networked: 53 relevant articles (15 outcomes, 12 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Yan, Victoria C: 3 articles (04/2022 - 07/2020)
2.	Baric, Ralph S: 3 articles (02/2022 - 09/2021)
3.	Babusis, Darius: 3 articles (01/2022 - 09/2021)
4.	Bannister, Roy: 3 articles (01/2022 - 09/2021)
5.	Bilello, John P: 3 articles (01/2022 - 09/2021)
6.	Cihlar, Tomas: 3 articles (01/2022 - 09/2021)
7.	Murakami, Eisuke: 3 articles (01/2022 - 01/2019)
8.	Subramanian, Raju: 3 articles (01/2022 - 09/2021)
9.	Alberer, Martin: 2 articles (01/2022 - 11/2021)
10.	Barrett, Kimberly T: 2 articles (01/2022 - 09/2021)

Related Diseases

1.	COVID-19 01/01/2022 - "Importantly, doses of GS-441524 lower than the 13 mg/kg dose used in the first-in-human trial may be effective against Covid-19. " 01/01/2022 - "Here, we evaluated GS-441524 for Covid-19 treatment based on studies reporting pharmacokinetic parameters of the agent in mice, rats, cats, dogs, monkeys, and the single individual in the first-in-human trial supplemented with information about its activity against severe acute respiratory syndrome coronavirus 2 and safety. " 08/01/2023 - "Exploration of the optimal GS-441524 trough concentration for treating COVID-19." 01/01/2022 - "The current article will focus on the discussion of interactions between GS-441524 and NSPs of VOCs to suggest potential application of GS-441524 in breakthrough SARS-CoV-2 infections. " 01/01/2022 - "Preclinical pharmacokinetics (PK) and In Vitro ADME properties of GS-441524, a potential oral agent for the treatment of Covid-19, were studied. "
2.	Feline Infectious Peritonitis 01/01/2022 - "This is the first report on a clinical follow-up and postmortem examination of a cat that had been cured of feline infectious peritonitis (FIP) with ocular manifestation by successful treatment with an oral multicomponent drug containing GS-441524. " 09/01/2023 - "GS-441524 has been successfully used to treat feline infectious peritonitis (FIP) in cats. " 01/01/2022 - "As previously demonstrated by our research group, the oral multicomponent drug Xraphconn® containing GS-441524 was effective at curing otherwise fatal feline infectious peritonitis (FIP) in 18 feline coronavirus (FCoV)-infected cats. " 11/05/2021 - "Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524." 09/01/2023 - "Nucleoside analog GS-441524 is effective in treating cats with feline infectious peritonitis (FIP). "
3.	Pneumonia (Pneumonitis) 08/01/2023 - "This study investigated the target GS-441524 trough concentration for symptom improvement in COVID-19 pneumonia. " 08/01/2023 - "GS-441524 trough concentration ≥70 ng/mL is a predictor of efficacy in COVID-19 pneumonia. " 01/01/2021 - "Co-administration of favipiravir and GS-441524 more efficiently reduced virus load in hamster lungs than did single administration of either drug for both the prophylactic and therapeutic regimens; prophylactic co-administration also efficiently inhibited lung inflammation in the infected animals. "
4.	Infections 01/01/2021 - "In this study, we confirmed that GS-441524 inhibits ASFV infection in porcine alveolar macrophages (PAMs) in a dose-dependent manner; GS-441524 significantly inhibited ASFV replication at different time points after ASFV infection, particularly at the early stages of viral replication. " 06/01/2018 - "In an experimental FIPV infection of cats, GS-441524 treatment caused a rapid reversal of disease signs and return to normality with as little as two weeks of treatment in 10/10 cats and with no apparent toxicity." 01/01/2022 - "At day 4 post-infection, GS-441524 (50 mg/kg, oral BID) and molnupiravir (150 mg/kg, oral BID) as monotherapy reduced infectious viral loads by 0.5 and 1.6 log10, respectively, compared to the vehicle control. " 06/01/2018 - "The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies."
5.	Urolithiasis 11/30/2023 - "Additional clinical studies are required to determine best screening practices for cats presented for urolithiasis during treatment with GS-441524."

Related Drugs and Biologics

1.	remdesivir
2.	Nucleosides
3.	Antiviral Agents (Antivirals)
4.	Prodrugs
5.	GC376
6.	Protease Inhibitors (Protease Inhibitor)
7.	Nucleotides
8.	Adenosine (Adenocard)
9.	GS-704277
10.	favipiravir

Related Therapies and Procedures

1.	Therapeutics
2.	Renal Replacement Therapy (Therapies, Renal Replacement)
3.	Renal Dialysis (Hemodialysis)
4.	Aftercare (After-Treatment)
5.	Oral Administration